AccuTheranostics® is a biotechnology company focused on the business of individualizing chemotherapy thereby dramatically improving outcomes for cancer patients.
AccuTheranostics® uses proprietary sophisticated technologies to provide patient-specific cancer diagnostic and prognostic information to oncologists in hospitals and oncology practices.
AccuTheranostics® is a leader in delineating the entire cellular composition of solid tumors.
Specimens are shipped in AccuTheranostics’® holding medium to our headquarters in Buffalo, New York where they undergo disaggregation, are subjected to drugs, single and in combination, and chemoresistance/sensitive profile is determined. The results will be provided within days of receiving the specimen to determine optimum treatment.
AccuTheranostics® is committed to advancing the science and practice of oncology therapeutics, with a strong emphasis on improving patient outcomes, enhancing patient quality and quantity of life.